PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
PolyPid unveiled an expanded pipeline strategy introducing PD01B, a new Kynatrix-based candidate for controlled-release local antibiotic treatment of diabetic foot infections. PD01B will be developed as a new NDA, with an FDA pre-IND meeting and first-in-human study expected in the second half of 2027. The company also confirmed all scheduled FDA interactions for D-PLEX100 remain on track ahead of its November 28, 2026 PDUFA goal date, with a U.S.
Key figures
- Drug Name
- PD01B (doxycycline via Kynatrix)
- Phase Of Trial
- pre-IND
- Pdufa date
- November 28, 2026
- First in human timing
- second half of 2027
- Pre ind meeting timing
- second half of 2027
- Dplex shield ii relative risk reduction
- 60% (p=0.0013)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.